Athma Dias: Limitations of PT and APTT in Predicting Thrombotic Risk
Athma Dias, Medical Laboratory Scientist at Teaching Hospital Ratnapura, shared a post on LinkedIn:
“The PT and APTT were never designed to predict thrombosis.
So why do we still rely on them as if they were?
A review published in February 2026 (MDPI, Biomolecules) makes something critically clear: while routine coagulation assays remain indispensable, they are fundamentally insensitive to hypercoagulable states and several emerging haemostasis biomarkers are now challenging the limits of what the coagulation laboratory can offer.
The core problem:
The Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) were designed to detect factor deficiencies causing Bleeding.
They screen only a fraction of the coagulation cascade under artificial conditions.
They tell us almost nothing about a patient’s actual thrombotic risk.
Yet thrombosis not bleeding is the leading cause of cardiovascular mortality globally.
Emerging global haemostasis assays are addressing this gap:
- Thrombin Generation Assay (TGA) measures the full kinetics of thrombin production and inhibition in plasma, capturing both pro- and anticoagulant balance in a single curve. Peak thrombin and endogenous thrombin potential (ETP) correlate with thrombotic and bleeding risk in ways the APTT cannot.
- Viscoelastic Testing (TEG/ROTEM) whole blood assays measuring clot formation, strength, and fibrinolysis in real time. Now guideline-recommended in major haemorrhage and cardiac surgery protocols.
- Thrombodynamics a novel spatial-temporal assay measuring clot growth from a surface-bound tissue factor activator, more closely mimicking in vivo vascular injury than any plasma-based assay.
- Neutrophil Extracellular Traps (NETs) emerging evidence published in Seminars in Thrombosis and Haemostasis (2026) confirms NETs as active participants in immunothrombosis, with NET biomarkers (citrullinated histone H3, cell-free DNA) showing promise as thrombotic risk markers in sepsis and cancer-associated thrombosis.
For the MLS in haemostasis, this evolution demands more than technical competency on the coagulation analyser.
It demands understanding haemostasis as a dynamic, spatially organised, cell-driven biological process not simply a cascade of clotting factors on a reagent strip.
Reference: Biomarkers of Coagulation Disorders MDPI Biomolecules, February 2026.
Is your laboratory using any global haemostasis assays beyond routine coagulation screening?”
Stay updated with Hemostasis Today.
-
Jun 25, 2026, 05:26Paola Mendez Hiraldo: Glenn Ruperto’s Stroke Recovery and the Power of Team-Based Care
-
Jun 25, 2026, 05:19Steven Bell: Lessons in Rapid Stroke Care from Vall d’Hebron University Hospital
-
Jun 25, 2026, 04:48Brianne Martin: Stroke Recovery Is More Than Medical Appointments
-
Jun 24, 2026, 22:30The Clinical Impact of Anaphylaxis-Associated Coagulopathy – JTH
-
Jun 24, 2026, 21:08Martin Haluzík: Semaglutide as a Strategy for Primary Prevention of Cerebrovascular Disease in RA
-
Jun 24, 2026, 19:43New ASH/ISTH 2026 Guidelines for Pediatric Anticoagulant Prophylaxis of VTE Are Now Live – Blood Journals Portfolio
-
Jun 24, 2026, 18:36Maryam Sardar: Timely Anticoagulation in SMV Thrombosis Complicating Acute Pancreatitis
-
Jun 24, 2026, 17:36Paul Whiteley: Neurodevelopmental and Autism Risks in Fetal and Neonatal Alloimmune Thrombocytopenia
-
Jun 24, 2026, 17:22Kavitha Dev: A Low Platelet Count Isn’t Always Critical, But It Should Never Be Ignored